Pharmaceutical Network November 17th Single clone antibody (hereinafter referred to as & ldquo; monoclonal antibody & rdquo;) biological products can definitely be called a gold mine in the pharmaceutical market。

 

monoclonal anti -antibody technology avoids the specific problems of antibody preparation，It can create a height and average one、Antibodies for only a specific antigen table，that is, higher accuracy & ldquo; guidance missile & rdquo;，Perform & ldquo; targeted strike & rdquo;stake betting app，Therefore, it is regarded as a tumor、Killer of diseases such as tuberculosis。1975，British scientists will fusion of lymphocytes of lymphocytes that produce antibodies，This technology has been established。Since then，Monoprotic biological products are followed by the drug market for its huge economic value。

 

Now，monoclonal antibody biological products in tumors、Autoimmune disease、Cardiovascular disease and diagnosis and treatment of infectious diseases have good results。Because this type of drug is particularly specific、Make significant effects and low toxicity，It is widely used clinically。This has also become the best reasons for the top list in the global drug sales ranking。

 

Global pharmaceutical giants will naturally not let go of this gold mine in this pharmaceutical industry。Roche、Abbott and Pfizer and other multinational pharmaceutical companies have scolded huge sums of money to seize the highlands。Among the top ten drugs in global sales in 2012，antibody drugs occupy about half。

 

Between several rounds of competing，Monoprotic drugs have become an important part of modern biopharmaceuticals，After reorganizing protein，Take out the climax of the second biopharmaceutical product。

 

When the outside world, especially the local enterprises, also see economic benefits、I hope to join this mining army，Everyone is blocked outside by technical barriers。

 

stake sports betting appBut now，With the patent expiration of a large number of monoclonal antibody biological products，Yingfliximab (Category、Johnson & Johnson)、Trangzumab (Herceptin、Roche) and Ada Mutterumimumi (Xiu Meile、Abbott), etc.，The monoclonal antibody biological products encountered in the encounter are all & ldquo; heavy bombs & rdquo;。

 

& ldquo; The expiration wave of patented drugs will leave a huge space for the spray growth of generic drugs。& rdquo; Now，The biological analog market is becoming increasingly active as more and more monoclonal biological product patents expire，SFDA Deputy Director of the Institute of Southern Medical Economics Tao Jianhong made such an analysis at a biotechnology forum at the end of October 2012，Cited by the media。

 

Due to the huge consumption potential，The Chinese market has become the key to robbing highlands for pharmaceutical companies。Current，Many pharmaceutical companies in the world have announced a strategic decision related to biotechnology drugs。

 

To develop、Production and sales of biological analog products，Fuji and Japan Coordinogenesis Kirin joint venture established & ldquo; Fuji-Xiehe Kirin Kirin Biological Preparation Company & RDQUO;，Subsequent，The joint venture announced the two biological imitation programs of Adam Mummy and Bedru。

 

Germany Merck also signed an agreement with a company，stake online sports bettingAfter that, the two sides jointly developed a imitation product for biological anticancer drugs。Pfizer and Mailan said that the two parties will sell more than 350 patents in the Japanese generic drug market，To open up the Japanese imitation market。

 

November 3, 2014，Guang Pharmaceutical Group, one of the largest pharmaceutical companies in China，& ldquo; Alliance & rdquo; Cuba's largest state -owned pharmaceutical company Cuba Biomedical Group。This cooperation involves the development of biomedical products、Production、Sales and Biomedical Technology Research and Development Platform Construction，Including the introduction of several innovative biopharmaceuticals with high -tech content in the Chinese market。

 

Guangyao Group thinks，This move allows the group to strive to enter the 100 billion club in 2016，By 2020, it will achieve 150 billion yuan in sales，and finally enter the world's top 500。

 

Actually，On the market of biological analogs，Some companies have passed & ldquo; alliance & rdquo;，and began to have a clear market positioning and business strategy。

 

Want to seize the market of Chinese biopagotics，Whether it is a multinational company or a local enterprise，You need to consider how to adapt to China's regulations and guidance principles。Current，Rules related to biological analogs are in a time window that is constantly exploring，How to grasp the opportunity stake sports betting appof this window，It depends on the company’s own ability。